12:00 AM
 | 
Oct 27, 2016
 |  BC Innovations  |  Emerging Company Profile

Microbiome gets skinny

How Xycrobe is harnessing the skin microbiome to deliver dermal therapies

While other microbiome companies battle intestinal diseases with cocktails of gut bacteria or bacteria-derived compounds, Xycrobe Therapeutics Inc. is moving beyond the gut with a platform that harnesses commensal bacteria in skin for continuous, local delivery of therapies for acne, psoriasis and other dermal diseases.

Xycrobe’s platform engineers bacteria to produce therapeutic compounds, using two species that occur naturally in the skin: Propionibacterium acnes, which reside in the hair follicles and sebaceous glands of the dermis; and an undisclosed species that lives on the surface.

When applied topically, the bugs home to their native layer of the skin to secrete the therapeutics.

CEO Thomas Hitchcock told BioCentury using two species allows simultaneous targeting of a larger number of skin regions to deliver “more of the therapeutic to more...

Read the full 639 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >